News and Trends 21 Mar 2025
Depression drug trials are failing—and placebos are to blame
In this article, we examine recent clinical trial failures and discuss potential pathways forward for antidepressant drug research.
About
Having completed a master’s programme in International Journalism from Cardiff University in 2022, I have written about various subjects including culture, politics, social justice, mental health, LGBTQ+ issues and gender. My undergraduate degree in life sciences has equipped me to explore my passion for reporting on health, science and the environment. When I’m not transcribing interviews and fretting about deadlines, I like to spend my time reading, watching movies, and making lousy mixtapes for a potential side career in rap music.
Articles by Roohi Mariam Peter
Best in Biotech 18 Mar 2025
Cancer vaccines: 11 biotechs to keep an eye out for
As various biotechs across the world specialize in the production of cancer vaccines, here are 11 companies making progress in the field.
Best in Biotech 13 Mar 2025
Nine biotechs thriving in Seattle in 2025
In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.
In Depth 12 Mar 2025
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
News and Trends 10 Mar 2025
23andMe: the collapse of a genomics giant
23andMe was once worth $6 billion and is now a penny stock. Layoffs, data breaches, and mass resignations plagued the genomics giant. How did it all unfold?
News and Trends 6 Mar 2025
Top biotech deals of February 2025
Find out about the top biotech partnership deal of February 2025. Small molecules, T-cell engagers, and RNA medicines, were all part of major collaborations.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 28 Feb 2025
Rare Disease Day: seven drugs awaiting approval in 2025
As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in 2025.
Best in Biotech 25 Feb 2025
Seven biotech spinouts to watch out for in 2025
Here are seven biotech spinouts to keep an eye out for this year that specialize in a number of therapeutic areas.
News and Trends 24 Feb 2025
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.
News and Trends 19 Feb 2025
Trade war: how new U.S. tariffs will impact the biopharma industry
The U.S. plans to impose trade tariffs on imports. How does this affect the biopharma industry?
In Depth 18 Feb 2025
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer.
In Depth 10 Feb 2025
Monoclonal antibodies: are they the key to treating Alzheimer’s disease?
A major stride in treating Alzheimer’s disease has been the development of monoclonal antibodies.
ADVERTISEMENT
